Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasm Malignant|Breast Cancer|Lung Neoplasm Malignant|Gastric Cancer|Neoplasm
Interventions: DRUG: SAR443216 IV|DRUG: SAR443216 SC
Sponsor: Sanofi